Best supportive care in lung cancer trials is inadequately described: a systematic review

被引:14
作者
Jack, B. [2 ,3 ]
Boland, A. [1 ]
Dickson, R. [1 ]
Stevenson, J.
Mcleod, C. [1 ]
机构
[1] Univ Liverpool, LRiG, Liverpool L69 3GE, Merseyside, England
[2] Marie Curie Palliat Care Inst, Liverpool, Merseyside, England
[3] Edge Hill Univ, Fac Hlth, Liverpool, Merseyside, England
关键词
best supportive care; lung cancer trials; QUALITY-OF-LIFE; ELDERLY-PATIENTS PTS; PHASE-III; RANDOMIZED-TRIAL; CHEMOTHERAPY; PLUS; SURVIVAL; BSC; VINORELBINE; MULTICENTER;
D O I
10.1111/j.1365-2354.2008.01064.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of the paper was to identify and discuss clinical terms associated with the availability and delivery of best supportive care for patients with lung cancer in randomised controlled clinical trials. Systematic review was carried out of relevant studies without language restrictions identified through Medline, EMBASE, Science Citation Index (Web of Science and ISI Proceedings) and Cochrane Library. Reference lists of retrieved articles were also searched to identify further studies. Articles describing randomised controlled trials or systematic reviews with a comparator arm of best supportive care for patients with lung cancer were studied. Definitions of best supportive care and elements of best supportive care were reported. Included clinical studies (n = 40) did not adequately describe or outline either the components or the delivery of best supportive care for patients in lung cancer trials. None of the identified studies provided a clear definition of a patient pathway in relation to best supportive care, or a clear list of components. Clinical studies are being conducted without a clear definition of the best supportive care provided in the comparator arms of trials. Inadequate definitions mean that all direct and indirect comparisons in trials comparing active treatments with best supportive care must be interpreted with caution.
引用
收藏
页码:293 / 301
页数:9
相关论文
共 43 条
[21]  
HOPWOOD P, 1999, SUPPORTIVE CARE C S7, V172
[22]  
Khan K.S., 2003, SYSTEMATIC REV SUPPO
[23]  
Klastersky J, 2001, LUNG CANCER-J IASLC, V34, pS95
[24]   Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer [J].
Medley, L ;
Cullen, M .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (04) :384-388
[25]  
NICE, 2004, IMPR SUPP PALL CAR A
[26]   Chemotherapy versus palliative care in non-small cell lung cancer [J].
Nicum, S ;
Cullen, MH .
ANTI-CANCER DRUGS, 2000, 11 (08) :603-607
[27]   Benefits of chemotherapy for quality of life in patients with advanced nonsmall-cell lung cancer [J].
Paesmans, M .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (04) :389-393
[28]  
Pallares C, 1996, ANN ONCOLOGY S5, V7, P89
[29]   Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer [J].
Ranson, M ;
Davidson, N ;
Nicolson, M ;
Falk, S ;
Carmichael, J ;
Lopez, P ;
Anderson, H ;
Gustafson, N ;
Jeynes, A ;
Gallant, G ;
Washington, T ;
Thatcher, N .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (13) :1074-1080
[30]   A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC) [J].
Roszkowski, K ;
Pluzanska, A ;
Krzakowski, M ;
Smith, AP ;
Saigi, E ;
Aasebo, U ;
Parisi, A ;
Tran, NP ;
Olivares, R ;
Berille, J .
LUNG CANCER, 2000, 27 (03) :145-157